Emperor preserved trial: Empagliflozin effective to treat heart failure

Published On 2022-02-10 14:00 GMT | Update On 2022-02-10 14:01 GMT

The EMPEROR-Preserved trial reports empagliflozin is superior to placebo in improving heart failure outcomes among patients with symptomatic stable heart failure with preserved ejection fraction, irrespective of diabetes status.

Incidence of Heart Failure in India appears to rise and estimates of prevalence range from 1.3 million to 4.6 million, with an annual incidence of 0.49–1.8 million. Several drugs are being investigated to manage heart failure.

The safety and efficacy of empagliflozin in patients with symptomatic heart failure was assessed in 2997 Patients randomized in a 1:1 design to either empagliflozin 10 mg or matching placebo of 2,991 patients in the trial.

Health-related quality of life in patients treated with empagliflozin had significant improvement in patients with meaningful improvements was reported in American College of Cardiology journal. Most routinely used drugs for Heart failure with reduced ejection fraction have not shown to be effective among patients, however this drug marks the change of treatment options.

Full View

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr. Nandita Mohan

Dr. Nandita Mohan is a practicing pediatric dentist with more than 5 years of clinical work experience. Along with this, she is equally interested in keeping herself up to date about the latest developments in the field of medicine and dentistry which is the driving force for her to be in association with Medical Dialogues. She also has her name attached with many publications; both national and international. She has pursued her BDS from Rajiv Gandhi University of Health Sciences, Bangalore and later went to enter her dream specialty (MDS) in the Department of Pedodontics and Preventive Dentistry from Pt. B.D. Sharma University of Health Sciences. Through all the years of experience, her core interest in learning something new has never stopped. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Emperor preserved trial: Empagliflozin effective to treat heart failure

Similar News

Weight Loss Drugs May Lower Risk of Heart Failure Hospitalization and Death by 40 Percent: Study

Is Your Mental Health Putting Your Heart at Risk? Study Sheds Light

No Benefit of Beta Blockers in Certain Heart Attack Patients: REBOOT Trial Finds

Study Reveals Potassium-Rich Foods May Lower Irregular Heartbeat Risk

Study Reveals Daily Intake of Five Mushrooms May Reduce Alzheimer's and Heart Disease Risk

Depression And Schizophrenia Double Heart Disease And Mortality Risks: Lancet Report

How Dangerous Is Irregular Sleep for Heart Failure Survivors? Study Finds Out

This Diet May Cut Risk of Cancer and Heart Disease Multimorbidity: Study Suggests